Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-10-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
自愿披露关于口服PROTAC药物HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about receiving approval from the Chinese National Medical Products Administration for clinical trials of a new drug (HP568) for treating a specific type of breast cancer. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, no management or board changes, no voting results, no earnings or annual reports, and no other financial or governance-related content. The document is an announcement of a regulatory approval related to clinical trials, which is a regulatory announcement but not a financial or governance report. Given the content and length (2020 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-15 Chinese
关于持股5%以上股东减持计划时间届满暨权益变动达1%的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from a company regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's holdings before and after the reduction, the number of shares sold, the time period of the reduction, and confirms that the reduction does not affect control of the company. The document includes tables of shareholding changes and confirms compliance with relevant securities laws. The document length is about 3,051 characters, which is relatively short and focused on a specific shareholder's transaction and equity change. This matches the description of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. It is not a full financial report, earnings release, or management report, nor is it a regulatory filing or report publication announcement. Therefore, the appropriate classification is MRQ with high confidence.
2024-10-14 Chinese
自愿披露关于HP515片用于治疗代谢性脂肪性肝炎（MASH）的临床试验申请获得美国FDA批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the FDA approval of a clinical trial application for a drug (HP515) developed by the company. It contains detailed information about the drug, its clinical trial status, and risk disclosures. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is a voluntary disclosure about a clinical trial approval, which is a regulatory announcement about the company's operational progress rather than a financial report or management change. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-09-13 Chinese
中信证券股份有限公司关于海创药业股份有限公司2024年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024年半年度持续督导跟踪报告" (2024 Semi-Annual Continuous Supervision Follow-up Report) issued by the sponsor (中信证券) for the listed company 海创药业股份有限公司. It contains detailed information about the sponsor's continuous supervision work, risk assessments, financial data for the first half of 2024, R&D progress, use of raised funds, and governance matters. The document includes substantive financial data and analysis for the half-year period ending June 30, 2024, including income, net profit, cash flow, assets, and R&D expenses. It is not merely an announcement or a certification but a comprehensive report covering the company's half-year performance and sponsor's supervision findings. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the document should be classified as IR. H1 2024
2024-09-13 Chinese
关于参加2024年半年度科创板制药及生物制品专场集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in a 2024 half-year performance explanation meeting organized by the Shanghai Stock Exchange. It references the company's 2024 half-year report already published on August 24, 2024, and provides details about the upcoming investor meeting (date, time, location, participation method). The document does not contain actual financial statements or detailed financial analysis but serves as a notice for an investor presentation event. The document length is short (1444 characters), and it primarily informs about the meeting rather than presenting financial data. Therefore, it fits best as an Investor Presentation (IP) announcement rather than the actual report or earnings release.
2024-09-06 Chinese
自愿披露关于HP515片用于治疗非酒精性脂肪性肝炎的临床试验获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about receiving approval from the Chinese National Medical Products Administration to conduct clinical trials for a new drug (HP515) targeting non-alcoholic steatohepatitis (NASH). It includes detailed information about the drug, its clinical trial approval, background on the disease, and risk warnings. The document is an official announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not a report publication announcement since it is the primary announcement itself. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-08-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.